BACKGROUND: We aimed to evaluate the efficacy of gene-directed enzyme-prodrug therapy (GDEPT) using cytosine deaminase in combination with uracil phosphoribosyl transferase (CDUPRT) against intraprostatic mouse androgen-refractory prostate (RM1) tumors in immunocompetent mice. The product of the fusion gene, CDUPRT, converts the prodrug, 5-fluorocytosine (5FC), into 5-fluorouracil (5FU) and other cytotoxic metabolites that kill both CDUPRT-expressing and surrounding cells, via a 'bystander effect'. METHODS: Stably transformed andogen-independent mouse prostate cancer (PC) cells, RM1-CDUPRT, -GFP or GFP/LacZ cells were used. To assess the local bystander effects of CDUPRT-GDEPT, immunocompetent C57BL/6 mice implanted with cell mixtures of RM1-GFP/CDUPRT and RM1-GFP cells in different proportions intraprostatically were treated with 5FC. Pseudo-metastases in the lungs were established by a tail vein injection of untransfected RM1 cells. At necropsy, prostate weight/volume and lung colony counts were assessed. Tumors, lymph nodes, spleens and lungs were frozen or fixed for immunohistochemistry. RESULTS: CDUPRT expression in RM1-GFP/CDUPRT cells or tumors was confirmed by enzymic conversion of 5FC into 5FU, using HPLC. Treatment of mice bearing intraprostatic RM1-GFP/CDUPRT tumors with 5FC resulted in complete regression of the tumors. A 'local bystander effect' was seen, even though only 20% of the cells expressed CDUPRT. More importantly a significant reduction in pseudo-metastases of RM1 cells in lungs indicated a 'distant bystander effect'. Immunohistochemical evaluation of the treated tumors showed increased necrosis and apoptosis, with decreased tumor vascularity. There was also a significant increase in tumour-infiltration by macrophages, CD4+ T and natural killer cells. CONCLUSIONS: We conclude that CDUPRT-GDEPT significantly suppressed the aggressive growth of RM1 prostate tumors and lung pseudo-metastases via immune mechanisms involving necrosis and apoptosis. Copyright (c) 2006 John Wiley & Sons, Ltd.
BACKGROUND: We aimed to evaluate the efficacy of gene-directed enzyme-prodrug therapy (GDEPT) using cytosine deaminase in combination with uracil phosphoribosyl transferase (CDUPRT) against intraprostatic mouse androgen-refractory prostate (RM1) tumors in immunocompetent mice. The product of the fusion gene, CDUPRT, converts the prodrug, 5-fluorocytosine (5FC), into 5-fluorouracil (5FU) and other cytotoxic metabolites that kill both CDUPRT-expressing and surrounding cells, via a 'bystander effect'. METHODS: Stably transformed andogen-independent mouseprostate cancer (PC) cells, RM1-CDUPRT, -GFP or GFP/LacZ cells were used. To assess the local bystander effects of CDUPRT-GDEPT, immunocompetent C57BL/6 mice implanted with cell mixtures of RM1-GFP/CDUPRT and RM1-GFP cells in different proportions intraprostatically were treated with 5FC. Pseudo-metastases in the lungs were established by a tail vein injection of untransfected RM1 cells. At necropsy, prostate weight/volume and lung colony counts were assessed. Tumors, lymph nodes, spleens and lungs were frozen or fixed for immunohistochemistry. RESULTS:CDUPRT expression in RM1-GFP/CDUPRT cells or tumors was confirmed by enzymic conversion of 5FC into 5FU, using HPLC. Treatment of mice bearing intraprostatic RM1-GFP/CDUPRTtumors with 5FC resulted in complete regression of the tumors. A 'local bystander effect' was seen, even though only 20% of the cells expressed CDUPRT. More importantly a significant reduction in pseudo-metastases of RM1 cells in lungs indicated a 'distant bystander effect'. Immunohistochemical evaluation of the treated tumors showed increased necrosis and apoptosis, with decreased tumor vascularity. There was also a significant increase in tumour-infiltration by macrophages, CD4+ T and natural killer cells. CONCLUSIONS: We conclude that CDUPRT-GDEPT significantly suppressed the aggressive growth of RM1 prostate tumors and lung pseudo-metastases via immune mechanisms involving necrosis and apoptosis. Copyright (c) 2006 John Wiley & Sons, Ltd.
Authors: Chun-Te Chen; Hirohito Yamaguchi; Hong-Jen Lee; Yi Du; Heng-Huan Lee; Weiya Xia; Wen-Hsuan Yu; Jennifer L Hsu; Chia-Jui Yen; Hui-Lung Sun; Yan Wang; Edward T H Yeh; Gabriel N Hortobagyi; Mien-Chie Hung Journal: Mol Cancer Ther Date: 2011-05-24 Impact factor: 6.261
Authors: Camilla L Christensen; Torben Gjetting; Thomas T Poulsen; Frederik Cramer; Jack A Roth; Hans S Poulsen Journal: Clin Cancer Res Date: 2010-04-06 Impact factor: 12.531
Authors: Cristina Ferrás; Joachim A F Oude Vrielink; Johan W A Verspuy; Hein te Riele; Anastasia Tsaalbi-Shtylik; Niels de Wind Journal: Mol Ther Date: 2009-05-26 Impact factor: 11.454
Authors: Irina V Alekseenko; Eugene V Snezhkov; Igor P Chernov; Victor V Pleshkan; Victor K Potapov; Alexander V Sass; Galina S Monastyrskaya; Eugene P Kopantzev; Tatyana V Vinogradova; Yuri V Khramtsov; Alexey V Ulasov; Andrey A Rosenkranz; Alexander S Sobolev; Olga A Bezborodova; Anna D Plyutinskaya; Elena R Nemtsova; Raisa I Yakubovskaya; Eugene D Sverdlov Journal: J Transl Med Date: 2015-03-04 Impact factor: 5.531
Authors: L Xing; X Sun; X Deng; K Kotedia; P B Zanzonico; E Ackerstaff; J A Koutcher; C C Ling; G C Li Journal: Cancer Gene Ther Date: 2013-05-31 Impact factor: 5.987